Michelle Dipp is a Co-Founder and Managing Partner at Biospring Partners. Michelle is passionate about life sciences and has over a decade of private equity and venture capital expertise. She currently serves on the Board of Directors of two Biospring portfolio companies, Abzena and Kiniciti.
Prior to Biospring, Michelle was a Managing Director at General Atlantic where she launched their first life sciences investment platform and led multiple investments including Ginkgo BioWorks (NYSE:DNA), Motif FoodWorks, PathAI, Immunocore (NASDAQ:IMCR) and Ocumension (HK:1477).
Before starting the life sciences platform at General Atlantic, Michelle was Co-Founder and General Partner of Longwood Fund, a leading healthcare investment firm based in Boston.
Prior to Longwood, Michelle was the Senior Vice President of the CEEDD at GlaxoSmithKline (NASDAQ:GSK), leading global business development and M&A. GSK acquired Sirtris Pharmaceuticals, Inc. (NASDAQ:SIRT), where Michelle served as Vice President of Corporate Development.
Michelle began her investment career at the Wellcome Trust after completing her medical training. She holds a Bachelor of Medicine and Bachelor of Surgery from the University of Oxford Medical School and a Doctor of Philosophy in Human Physiology from the University of Oxford.
Being born and raised on the border in El Paso, Texas, Michelle cares deeply about her community and currently serves on the following boards:
-Trustee Advisory Board for Beth Israel Deaconess Medical Center
-Advisory Board for the Women’s Foundation of Boston, focused on serving women and girls in need
- Board of Directors for Life Science Cares, focused on alleviating poverty in the Boston community
- Rockefeller University Council
- Advisory Council for the American Museum of Natural History
- Co-Founding Member of the Bowman Fund, Brasenose College Boat Club, Oxford University
-World Economic Forum’s Young Global Leaders (2015-2020)
Michelle lives in New York with her husband and enjoys hiking and cycling.